Looking to publish in Human Vaccines & Immunotherapeutics? Livewrite integrates seamlessly with Word to help you write, edit, and format faster.
Existing customer loginHuman Vaccines & Immunotherapeutics is an international open access peer-reviewed journal focused on human vaccinology and immunotherapy. It publishes research on novel vaccines and immunotherapeutics, preclinical studies, clinical trials, disease mechanisms, licensed products, vaccine acceptance and hesitancy, policy, safety, surveillance, epidemiology, pharmaco-economics, and related public health topics. The journal operates single-anonymized peer review, is affiliated with the International Society for Vaccines and the Association for Cancer Immunotherapy, and has been fully open access since Volume 18 in 2022.
Looking to publish in Human Vaccines & Immunotherapeutics? Livewrite integrates seamlessly with Word to help you write, edit, and format faster.
Existing customer loginSubmission Instructions
Human Vaccines & Immunotherapeutics accepts the following article types. Click on an article type to view submission instructions.
Research Articles
Review Article
State-Of-The-Art Reviews
Case Report
Rapid Communication
Mini-Reviews
Recent Publications
Cross-protective immune responses to pneumococcal serotype 6A following vaccination with 6B-containing pneumococcal conjugate vaccines: A systematic review and meta-analysis
Nitin Shah, S. Shyam. Kukreja, A. J. Chitkara, Ganesh Kulkarni, Ravi Kumar, Geetha Nagaraj, Archana Toppo, Usha Rani H Patted
The importance of RSV vaccination for at-risk adults aged 18–59: An expert opinion with an Italian perspective
Massimo Andreoni, Paola Rogliani, Massimo Volpe, Matteo Ricco, Caterina Rizzo, Cinzia Ortega, Barry Rodgers-Gray, Nicola Waghorne
Concurrent Schistosoma mansoni infection suppresses induction of HIV-1 Env-specific antibodies in a DNA-MVA-gp140 Env vaccine regimen in rhesus macaques
Gerald K. Chege, Rosamund E. Chapman, Asisipho Mzukwa, Alana T. Keyser, Craig H. Adams, Michiel T. van Diepen, Nicola Douglass, Nonkululeko Mzindle, Qiniso Mkhize, Penny L. Moore, Anna-Lise Williamson
Transmission dynamics of pertussis in China (2015–2024): A SEIARV compartmental model with waning immunity, annual parameter fitting, and stochastic forecasting for 2025–2027
Nan Zhou, Jin Zhao
Exploring RSV prevention among pregnant people and healthcare professionals in Aotearoa, New Zealand
Amber Young, Noni Richards, Reem Abbas, Emma Best, Samantha Marsh, Esther Willing, Ashleigh Rak, Yasmin Mohamed, Margie Danchin, Nadia A. Charania
Frequently asked questions
How long does it take to publish?
25 days average from submission to first decision; 48 days average from submission to first post-review decision; 14 days average from acceptance to online publication.
Reformat to Human Vaccines & Immunotherapeutics using Livewrite PremiumIs a cover letter required?
A cover letter is not used for APC waiver requests. Waiver requests must be made at the time of online submission, not in a cover letter.
Reformat to Human Vaccines & Immunotherapeutics using Livewrite PremiumWhat are the publication costs?
Open access costs may be covered by a Taylor & Francis open access agreement; journal-specific charges vary.
Reformat to Human Vaccines & Immunotherapeutics using Livewrite Premium